Plus Therapeutics, Inc. (NASDAQ:PSTV) went up by 3.27% from its latest closing price when compared to the 1-year high value of $16.00 and move down -532.41%, while PSTV stocks collected -3.16% of loss with the last five trading sessions. Press Release reported 10 hours ago that Plus Therapeutics, Inc. receives FDA Orphan Drug Designation for its Novel Glioblastoma Treatment
Plus Therapeutics, Inc. (NASDAQ:PSTV) Worth an Investment?
Plus Therapeutics, Inc. (NASDAQ: PSTV) The 36 Months beta value for PSTV stocks is at 0.53, while 1 of the analysts out of 1 who provided ratings for Plus Therapeutics, Inc. stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $5.00 which is -$2.53 below current price. PSTV currently has a short float of 7.46% and public float of 3.98M with average trading volume of 432.83K shares.
PSTV Market Performance
PSTV stocks went down by -3.16% for the week, with the monthly jump of 0.82% and a quarterly performance of 43.27%, while its annual performance rate touched -84.03%. The simple moving average for the period of the last 20 days is -6.71% for PSTV stocks with the simple moving average of 20.43% for the last 200 days.
PSTV Stocks 1.90% Far from 50 Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, Plus Therapeutics, Inc. was unable to take a rebound, for now settling with -84.19% of loss for the given period.
The stock volatility was left at 10.07%, however, within the period of a single month, the volatility rate increased by 7.68%, while the shares sank at the distance of -5.58% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +12.96% upper at the present time.
In the course of the last 5 trading sessions, PSTV went up by +3.28%, which changed the moving average for the period of 200 days to the total of +5.87% of gains for the stock in comparison to the 20-day moving average settled at $2.70. In addition, Plus Therapeutics, Inc. saw 2.08% in overturn over the period of a single year with a tendency to cut further gains.
PSTV Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Plus Therapeutics, Inc. (PSTV), starting from Lenk Robert P, who bought 3,000 shares at the price of $2.49 back on Aug 25. After this action, Rushing now owns 3,000 shares of Plus Therapeutics, Inc., valued at $7,465 with the latest closing price.
Petersen Greg, the Director of Plus Therapeutics, Inc., bought 10,000 shares at the value of $2.80 during a trade that took place back on Aug 13, which means that Petersen Greg is holding 20,000 shares at the value of $28,000 based on the most recent closing price.
PSTV Stock Fundamentals
The current profitability levels are settled at -52.26 for the present operating margin. The net margin for Plus Therapeutics, Inc. stands at -46.91. Total capital return value is set at -22.46, while invested capital returns managed to touch -93.39. Equity return holds the value -176.00%, with -9.90% for asset returns.
Based on Plus Therapeutics, Inc. (PSTV), the company’s capital structure generated 1,032.16 points for debt to equity in total, while total debt to capital is set at the value of 91.17. Total debt to assets is settled at the value of 51.54 with long-term debt to equity ratio rests at -1.97 and long-term debt to capital is 55.69.
The value for Enterprise to Sales is -0.33 with debt to enterprise value settled at -5.21. The receivables turnover for Plus Therapeutics, Inc. is 8.28 with the total asset turnover at the value of 0.30. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.